MA-VERTEX-PHARMA
7.4.2020 15:02:17 CEST | Business Wire | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Vertex Foundation, a nonprofit charitable foundation, commits to make donations totaling $5 million in 2020 to support global COVID-19 relief efforts, including doubling its match for employees’ charitable donations to eligible organizations responding to the COVID-19 pandemic. The Vertex Foundation’s funds will help organizations that are providing emergency relief and assistance in the global communities where Vertex employees live and work, with a focus on providing health care and supplies and support for vulnerable populations.
“The Vertex Foundation’s immediate priority is to address the unprecedented needs of our local communities resulting from COVID-19. We are focused on providing funding to organizations that can provide immediate access to health care and health supplies — including testing and personal protective equipment — in hard-hit countries, and those who are working on-the-ground to provide vulnerable populations with food, care and education,” said Michael Parini, Chairman of the Vertex Foundation and Executive Vice President and Chief Legal, Administrative and Business Development Officer at Vertex.
Essential Health Care and Health Supplies
The Vertex Foundation today announced that it has committed $1 million to Direct Relief, an organization dedicated to providing essential supplies for health workers, such as critical personal protective equipment, N-95 masks, battery powered oxygen concentrators and ventilators. The Foundation’s donation will help establish Direct Relief’s European relief efforts, including in UK, Spain, France and Germany, and help the organization expand its response in the U.S.
“Direct Relief is deeply grateful to the Vertex Foundation for their generosity in supporting COVID-19 relief efforts in the U.S. and allowing us to ramp up our efforts in Europe,” said Thomas Tighe, Direct Relief President and CEO. “Their significant commitment in this challenging time is greatly appreciated.”
In addition, the Vertex Foundation is also supporting the following organizations to help provide essential health care and health supplies:
- Partners HealthCare in Boston , to support an integrated COVID-19 response including delivering patient testing across the community and through donations of the company’s personal protective equipment;
- CDC Foundation’s Emergency Response Fund , to provide enhanced public health laboratory capacity, develop and deploy technology tools, and support state and local health departments;
- French Red Cross (Croix Rouge) , to support on-the-ground front-line response and humanitarian relief efforts to enhance the government’s response in France;
- Scripps Health Foundation in San Diego , to support their drive-through testing centers and fully fund one center for five weeks; and
- EMERGENCY Ong Onlus in Italy , to provide medical care to the most vulnerable populations in the Lombardy region of Italy, where the crisis is severe.
Support for Vulnerable Populations
Last month, the Vertex Foundation donated $1 million to help establish the Boston Resiliency Fund , which is coordinating fundraising and philanthropic efforts to assist Boston residents whose health and well-being are most immediately impacted by the COVID-19 pandemic.
“The outpouring of support and generosity that we've seen from our private and philanthropic partners as we navigate these difficult times together has been tremendous,” said Mayor Martin J. Walsh. “Jeff Leiden and the Vertex Foundation were instrumental in getting the Boston Resiliency Fund off the ground to support our frontline workers and our residents most in need, and I thank them for their continued efforts and for going above and beyond to support relief efforts for our residents.”
In addition, the Vertex Foundation announced today that it has made additional donations to the following organizations around the world to provide essential community support for vulnerable populations — specifically food, care and education:
- The Trussell Trust in the UK , to support its nationwide network of food banks and provide emergency food and support needed because of COVID-19; to build on and support the development of a national helpline and referral system to enable food banks to meet increased demand for emergency food;
- Crisis in the UK , to help with on-the-ground support for the homeless including “essentials” packages of food, tissues and hand sanitizers;
- Age UK , to support older people, particularly those ages 70 and older, who are worst hit by the pandemic physically and emotionally;
- Caritas in Spain , to provide home delivery of food to elderly and support homeless shelters and health needs in Madrid;
- Les Restos du Coeur in France , to support food distribution to the neediest and provide hygiene products to volunteers distributing the food;
- Cesvi in Italy , to provide at-home health and food to the elderly in Bergamo and Brescia;
- Feeding San Diego , to provide healthy food through emergency food distribution centers and provide food to San Diego students who rely on free meals;
- Community Foundation of Western Massachusetts , to support its COVID-19 Response Fund for the Pioneer Valley;
- The Food Bank of Western Massachusetts , to provide 400,000 meals for its emergency feeding programs across Hampden, Hampshire, Berkshire and Franklin counties; and
- United Way of Greater Fall River , to support its COVID-19 relief and recovery efforts across the Southcoast Massachusetts community.
About The Vertex Foundation
The Vertex Foundation is a nonprofit charitable foundation. It seeks to improve the lives of people with serious diseases and in its communities through education, innovation and health programs. Established in 2017, the Foundation is a long-term source of charitable giving and is part of Vertex Pharmaceuticals’ corporate giving commitment. To learn more about the Vertex Foundation, visit https://www.vrtx.com/responsibility/vertex-foundation .
About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of genetic and cell therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including 10 consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on Facebook, Twitter, LinkedIn, YouTube and Instagram.
(VRTX-GEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005509/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
Sutherland Launches FinAI Hub to Industrialize Agentic AI for Banking and Financial Services6.3.2026 14:00:00 CET | Press release
A domain-trained AI agent workforce enables production-scale AI across regulated financial institution operations Today, Sutherland announced the launch of Sutherland FinAI Hub, an enterprise Agentic AI platform built exclusively for Banking and Financial Services. As financial institutions accelerate AI adoption, many initiatives remain confined to pilots, unable to scale across legacy systems and core operations. Sutherland FinAI Hub is designed to help close that gap. FinAI Hub is an innovation ecosystem where Sutherland works with clients to design, prototype, and scale Agentic AI workflows across core operations. At launch, the platform brings together a large and expanding workforce of domain-trained AI agents purpose-built for financial institutions, supporting functions across retail banking, payments, cards, consumer and commercial lending, servicing, back office, risk and compliance functions. These modular agents can operate independently or be orchestrated across end-to-end
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
